Provided by Tiger Trade Technology Pte. Ltd.

GRAIL, Inc.

76.58
-2.9600-3.72%
Post-market: 77.891.31+1.71%18:46 EDT
Volume:381.02K
Turnover:29.44M
Market Cap:3.42B
PE:-7.86
High:81.87
Open:81.87
Low:75.61
Close:79.54
52wk High:118.84
52wk Low:30.82
Shares:44.67M
Float Shares:40.64M
Volume Ratio:0.44
T/O Rate:0.94%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-9.7487
EPS(LYR):-11.1105
ROE:-16.12%
ROA:-12.03%
PB:1.35
PE(LYR):-6.89

Loading ...

Canaccord Genuity Keeps Their Buy Rating on GRAIL Inc (GRAL)

TIPRANKS
·
Jun 01

Grail's Galleri Test Improves Cancer Detection in Pathfinder 2 Trial

MT Newswires Live
·
Jun 01

Grail presents ‘positive’ performance, safety results from Pathfinder 2 study

TIPRANKS
·
Jun 01

Grail reports results from NHS-Galleri trial in presentation at ASCO meeting

TIPRANKS
·
Jun 01

Grail Presents Pathfinder 2 Results of More Than 35,000 Participants Showing the Galleri® Test Substantially Increased Cancer Detection With Robust Performance and Favorable Safety at 2026 Asco Annual Meeting

THOMSON REUTERS
·
May 31

BRIEF-Grail Reports Full Results From Nhs-Galleri Trial Demonstrating Substantial Reduction In Stage Iv Cancer Diagnoses

Reuters
·
May 30

Grail - Galleri Blood Test Reduces Stage Iv Diagnoses by 22% in Second and 26% in Third Rounds

THOMSON REUTERS
·
May 30

Grail Reports Full Results From Nhs-Galleri Trial Demonstrating Substantial Reduction in Stage Iv Cancer Diagnoses at 2026 Asco Annual Meeting

THOMSON REUTERS
·
May 30

Grail Inc - No Reduction Observed in Combined Primary Endpoint of Stage Iii/Iv Cancers in Aggregate

THOMSON REUTERS
·
May 30

Grail grants 34,350 RSUs to 56 new hires under inducement equity plan

Reuters
·
May 28

Grail Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
May 28

Analysts Offer Insights on Healthcare Companies: ICU Medical (ICUI) and GRAIL Inc (GRAL)

TIPRANKS
·
May 27

Grail to present at Goldman Sachs Global Healthcare Conference

Reuters
·
May 27

Grail to present at Jefferies Global Healthcare Conference

Reuters
·
May 22

Grail posts MCED study presentation on reducing emergency cancer diagnoses via ED

Reuters
·
May 19

Grail Q1 net loss narrows 12% to $93.2 million; revenue rises 28% to $40.8 million

Reuters
·
May 08

Grail price target lowered to $70 from $82 at Baird

TIPRANKS
·
May 07

GRAIL (GRAL) Q1 2026 Heavy US$93 Million Loss Tests High 16.5x Sales Multiple

Simply Wall St.
·
May 07

Grail Is Maintained at Neutral by Piper Sandler

Dow Jones
·
May 06

Stock Track | GRAIL Inc Soars 9.13% Intraday on Analyst Buy Rating Optimism

Stock Track
·
May 06